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Panax notoginseng (PN) is a traditional Chinese herb experimentally proven to have anti-inﬂammatory eﬀects, and it is used
clinically for the treatment of atherosclerosis, cerebral infarction, and cerebral ischemia. This study aimed to determine the anti-
inﬂammatory eﬀects of PN against bleomycin-induced pulmonary ﬁbrosis in mice. First, in an in vitro study, culture media
containinglipopolysaccharide(LPS)wasusedtostimulatemacrophagecells(RAW264.7cellline).TNF-αandIL-6levelswerethen
determined before and after treatment with PN extract. In an animal model (C57BL/6 mice), a single dose of PN (0.5mg/kg) was
administered orally on Day 2 or Day 7 postbleomycin treatment. The results showed that TNF-α and IL-6 levels increased in the
culturemediaofLPS-stimulatedmacrophagecells,andthiseﬀectwassigniﬁcantlyinhibitedinaconcentration-dependentmanner
by PN extract. Histopathologic examination revealed that PN administered on Day 7 postbleomycin treatment signiﬁcantly
decreased inﬂammatory cell inﬁltrates, ﬁbrosis scores, and TNF-α,T G F - β,I L - 1 β, and IL-6 levels in bronchoalveolar lavage ﬂuid
when compared with PN given on Day 2 postbleomycin treatment. These results suggest that PN administered in the early ﬁbrotic
stage can attenuate pulmonary ﬁbrosis in an animal model of idiopathic pulmonary ﬁbrosis.
1.Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a fatal disease char-
acterized by progressive and irreversible lung ﬁbrosis, with-
out any known eﬀective therapy [1]. Although associated
molecular mechanisms remain poorly understood, hallmark
pathological features include ﬁbroblastic foci representing
focal areas of active ﬁbrogenesis, ﬁbroblast replication, and
extracellular matrix (ECM) deposition. Myoﬁbroblasts, by
secreting ECM molecules, which include ﬁbrillar collagens,
ﬁbronectin, elastin, and proteoglycans, play an important
role in the pathogenesis of pulmonary ﬁbrosis [2, 3]. Various
theories are posited to explain this process, such as the
production of ﬁbroblast chemotactic factors by activated
alveolar epithelial cells and the release of growth factors
involved in reepithelization, such as transforming growth
factor beta (TGF-β), platelet-derived growth factor (PDGF),
insulin-likegrowthfactor-1(ILGF-1),andendothelin-1(ET-
1) [4–7]. Inﬂammatory cytokines, including tumor necrosis
factor (TNF) and interleukin (IL), are also important in the
development of pulmonary ﬁbrosis [8].
Panax notoginseng (PN) is a highly valued traditional
Chinese medicine that reportedly has a variety of pharma-
cologic activities. Clinically, PN is used in the treatment
of acute ischemic stroke [9] and cardiovascular disease
[10]. In experimental studies, its documented pharmacolog-
ical eﬀects include anti-inﬂammatory, haemostatic, antiox-
idant, hypolipidemic, hepatoprotective, renoprotective, and
estrogen-like activities [11]. A variety of studies have also
shown PN to have anti-inﬂammatory activity, probably via
COX-2, toll-like receptor, or nuclear factor kappa B (NF-
κB) signaling pathways [12–17]. Moreover, PN may inhibit2 Evidence-Based Complementary and Alternative Medicine
hepatic or renal ﬁbrosis when these organs are damaged
[18–21]. Studies addressing the anti-inﬂammatory eﬀect of
PN on lung disease are quite limited, and only one report
shows that PN attenuates acute lung injury induced by
intestinal ischemia/reperfusion in rats [22].
Previous studies have shown that blocking TGF-β and
TNF-αmayattenuatethedevelopmentofpulmonaryﬁbrosis
[23, 24]. Accordingly, this study hypothesized that PN
inhibits pulmonary ﬁbrosis by suppressing TNF-α and
TGF-β [19, 25] with the aim of evaluating in a murine model
itsprotectiveeﬀectsonbleomycin-inducedpulmonaryﬁbro-
sis in terms of survival rate, lung tissue histology, ﬁbrosis
score, and inﬂammatory cytokines.
2.MaterialsandMethods
2.1. Preparation of Panax notoginseng (PN) Extract. PN was
purchased from Fu Tan Pharmaceutical Co., Ltd, Taiwan
in 2006. Air-dried ﬂowers (50g) of PN were cut into
small pieces and extracted with 80% methanol in a reﬂux
condenser for 5h. The methanol extract of PN was ﬁltered
through Whatman No.1 paper and concentrated in a
vacuum evaporator (18.74g; 37.48% yield). The lyophilized
powder was dissolved in culture-grade dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St. Louis, MO, USA) prior to use
and then sterile-ﬁltered through a 0.45μMM i l l i p o r eﬁ l t e r .
2.2. Cell Culture. Macrophages (RAW 264.7 cell line) were
kept in an atmosphere of 95% air and 5% CO2 and
incubated in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
GibcoBRL, Grand Island, NY, USA) supplemented with 5%
heat-inactivated fetal bovine serum (FBS; Hyclone, Logan,
UT, USA), 100g/mL streptomycin, and 100U/mL penicillin
(GibcoBRL). Cells were maintained via weekly passage, and
cell viability was determined by a 3-(4,5-dimethyl-thiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) reduc-
tion assay. The cells used for experimentation were at 60%–
80% conﬂuence.
Brieﬂy, cells were preincubated overnight in 24-well
plates at a density of 2 × 105 cells per well and then
washed with phosphate-buﬀered saline (PBS). Cells with
various concentrations of PN extract were treated with
lipopolysaccharide (LPS) (Escherichia coli 055:B5, Sigma-
Aldrich) for 24h and grown in media containing MTT
(0.5mg/mL) at 37◦C for 4h. After removing the culture
supernatants, the resulting dark blue crystals were dissolved
with DMSO. Absorbance values were read at 550nm on an
automated SpectraMAX 340 (Molecular Devices, Sunnyvale,
CA, USA). All determinations were conﬁrmed by at least
three independent experiments.
The culture supernatants collected from treated cells
wereusedtodeterminetheinhibitoryeﬀectsofPNextracton
the production of TNF-α and IL-6 as measured by enzyme-
linked immunosorbent assay (ELISA). The samples were
analyzed according to the manufacturer’s recommendations
with mouse cytokine-speciﬁc DuoSet ELISA Development
System (R&D Systems, Minneapolis, MN, USA). Concen-
trations of TNF-α and IL-6 were calculated according to
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Figure 1: Experimental protocol for bleomycin-induced pul-
monary ﬁbrosis and administration of Panax notoginseng (PN) at
diﬀerent time points.
a standard curve generated using each of the recombinant
cytokines in the ELISA kits.
2.3. Animals and Experimental Protocols. Healthy male
C57BL/6 mice weighing 200 to 250g from the experimental
research center of China Medical University (Taichung,
Taiwan) were housed in a speciﬁc cage with a 12-h light/dark
cycle and with free access to water and food ad libitum.
The institutional committee for animal care approved all
procedures involving animals. To examine the safety dosage,
0.5mg/kg, 1mg/kg, and 2mg/kg of PN were administered
orally to the mice. No mice died during the 14-day admin-
istration of 0.5mg/kg PN, while the 14-day mortality rate
was67%formiceadministered2mg/kgPN.Thus,0.5mg/kg
PN was used as the experimental dose administered via oral
gavage.
For instillation, animals were ﬁrst anesthetized with
ether, and bleomycin (Aventis, Brussels, Belgium) suspended
in sterile NaCl 0.9% at 1U/kg was then instilled transorally
into the animals’ lungs via the trachea. Control mice (n = 6)
were instilled with a corresponding volume of NaCl 0.9%
(NS group). The remaining animals were divided randomly
into the following three groups: (1) the BL group included
mice (n = 6) instilled with bleomycin; (2) the BP group
included mice (n = 6) instilled with bleomycin and PN was
administered orally on Day 2 post-bleomycin instillation;
and (3) the BD group included mice (n = 6) instilled with
bleomycin and PN was administered orally on Day 7 post-
bleomycin instillation (Figure 1) .T h em i c ei nt h eB La n dB P
groups were sacriﬁced on Days 7, 14, or 21 after treatment,
whereas the mice in the BD group were sacriﬁced only on
Day 14 or 21 because PN was administered on Day 7 post-
bleomycin instillation.
2.4. Histopathologic Analysis. After sacriﬁce, the right lower
lobe of the lung from each animal was harvested and ﬁxed
in 10% formalin and embedded in paraﬃn after 48h. Ten
consecutive longitudinal sections (4μm thick) of the lungs
were stained with hematoxylin and eosin (H&E stain). The
resulting slides were examined under light microscope at a
photodocumentation facility.Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: PN extract inhibited LPS-induced inﬂammatory cytokines in macrophage cells. (a) MTT assay to evaluate cell viability at various
concentrations of PN. (b) IL-6 levels increased in the culture media of LPS-stimulated macrophage cells and signiﬁcantly decreased with
400μg/mL of PN. (c) The levels of TNF-α were signiﬁcantly inhibited in a concentration-dependent manner by treatment with PN extract.
Data are presented as means ± SEM. (PN unit: μg/mL).
To grade the extent of lung ﬁbrosis, each successive
ﬁeld was individually assessed for the severity of inter-
stitial ﬁbrosis using the semiquantitative grading system
as previously described [26]. The entire lung section was
reviewed under ×100 magniﬁcation. For each of the 30 to 35
microscopic ﬁelds that were reviewed, a score ranging from
0 (normal lung) to 8 (total ﬁbrosis) was assigned. Criteria
for grading pulmonary ﬁbrosis were as follows: Grade 0,
normallung;Grade1,minimalﬁbrousthickeningofalveolar
or bronchial walls; Grades 2-3, moderate thickening of walls
without obvious damage to lung architecture; Grades 4-5,
increased ﬁbrosis with deﬁnite damage to lung architecture
andformationofﬁbrousbandsorsmallﬁbrousmass;Grades
6-7, severe distortion of structure and large ﬁbrous areas;
“honeycomb lung” was also placed in this category; and
Grade 8, total ﬁbrotic obliteration of the ﬁeld. The mean
score of all ﬁelds was taken as the ﬁbrosis score of that lung
section.
To assess the bronchoalveolar lavage ﬂuid (BALF), the
right main bronchus was clamped and bronchoalveolar
lavage of the left lung was performed three times with 2mL
normal saline solution. BALF was pooled and centrifuged
at 1200g for 10min, and the supernatant was harvested for
cytokine analysis. BALF levels of TGF-β,T N F - α,I L - 1 β and
IL-6 were quantiﬁed using ELISA speciﬁc for the previously
mentioned mouse cytokines (Biosource International, Niv-
elles, Belgium).
2.5. Statistics. All statistical analyses were performed using a
commercial statistical software (SPSS for Windows, version
15.0, Chicago, IL, USA). Data are presented as the mean plus
or minus the standard error of the mean of three samples
and are representative of three independent experiments.
Diﬀerences between two means were analyzed by Student’s
t-test. Data sets with multiple comparisons were evaluated
by one-way analysis of variance (ANOVA) with Dunnett’s
post test. Values of P<. 05 were deemed to be statistically
signiﬁcant.
3. Results
3.1. In Vitro Study. The MTT assay was used to evaluate
cell viability at various concentrations of PN (100, 200,
and 400μg / m L ) .T h eO Do ft h ev a r i o u sP Nc o n c e n t r a t i o n s4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Representative sections of lungs from mice in the three treatment groups. Lung tissues were obtained on Days 7, 14, and 21 after
instillation of bleomycin and physiologic saline (H&E stain, ×100 magniﬁcation).
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Figure 4: Pulmonary ﬁbrosis scores of the diﬀerent groups on
Days 7, 14, and 21 post-bleomycin treatment. Data are presented
as means ± SEM.
showed no signiﬁcant diﬀerence (0.51, 0.46, and 0.47, resp.)
(Figure 2(a)).Furtherinvestigation oftheanti-inﬂammatory
eﬀects of PN on LPS-stimulated macrophages using ELISA
showed that TNF-α and IL-6 levels were increased. At
diﬀerent concentrations of PN (100, 200, and 400μg/mL),
the corresponding levels of IL-6 were 333.68, 331.88, and
197.40pg/mL, respectively. At PN 400μg/mL, the levels of
IL-6 were signiﬁcantly reduced (P<. 05) (Figure 2(b)). At
increasing concentrations of PN (100, 200, and 400μg/mL),
the levels of TNF-α were 171.73, 111.14, and 77.22pg/mL,
respectively. Thus, treatment with PN extract signiﬁcantly
reduced TNF-α levels in a concentration-dependent manner
(Figure 2(c)).
3.2. Lung Histology and Pulmonary Fibrosis Score.
Histopathologic examination of H&E-stained lung tissue
sections showed an obvious inﬂammatory response on Day
7 post-bleomycin instillation, and the lungs progressed to
ﬁ b r o s i so nD a y1 4 ,w h i c hb e c a m ee v e nm o r es e v e r eo n
Day 21. The lung parenchyma of the bleomycin-treated
group (BL group) showed severe epithelial degeneration,
inﬂammatory cell inﬁltration, ﬁbrosis, vascular congestion,Evidence-Based Complementary and Alternative Medicine 5
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Figure 5: (a) IL-1β,( b )T N F - α, (c) IL-6, and (d) TGF-β levels in bronchoalveolar lavage ﬂuid (BALF) of mice treated with saline (NS),
bleomycin (BL), PN since Day 2 post-bleomycin treatment (BP), or PN since Day 7 post-bleomycin treatment (BD). Data are presented as
means ± SEM (n = 6 for each group).
and disturbance of alveolar structure (Figures 3(b), 3(e),
and 3(h)), while the PN-treated bleomycin group (BP
group) showed moderate inﬂammatory cell inﬁltration, and
mild epithelial degeneration, ﬁbrosis, vascular congestion,
and disturbance of alveolar structure (Figures 3(c), 3(f),
and 3(i)).
Using Fast Green stain, the severity of interstitial ﬁbrosis
was assessed using a semiquantitative grading system [26].
Lung tissues from the bleomycin-treated group (BL group)
exhibited signiﬁcant bleomycin-induced lung injury. As
shown in Figure 4, pulmonary ﬁbrosis scores were higher in
the BP group than in the BL group, although not statistically
signiﬁcant (P = .22). In contrast to Day 7, the pulmonary
ﬁbrosis scores of the BP group were signiﬁcantly lower than
those of the BL group on Days 14 and 21 (P = .009 and .004,
resp.). In the BD group, the pulmonary ﬁbrosis scores were
signiﬁcantly reduced on Days 14 and 21.
3.3. Proinﬂammatory Cytokines in BALF. In the BL group,
levels of TGF-β,T N F - α,I L - 1 β, and IL-6 in BALF were
signiﬁcantly increased on Days 7, 14, and 21 after bleomycin
injection, but the levels of these cytokines were signiﬁcantly
reduced in the BD group (bleomycin with PN-Day 7)
comparedwiththeBLgrouponDays14and21(Figure 5).In
contrast to the BP group (bleomycin with PN-Day 2), TGF-β
levels were signiﬁcantly increased on Day 7, similar to levels
of the BL group but higher on Day 14.
4. Discussion
Idiopathic pulmonary ﬁbrosis (IPF) is a progressive and
fatal pulmonary disease without proven drug therapies [4].
Its clinical features vary, with diﬀerences in age at onset,
presentation, and clinical course [27]. This study shows that
PN administered on Day 7 post-bleomycin treatment results
in signiﬁcant reductions in pulmonary ﬁbrosis scores and
cytokines in mice, indicating that PN can be an eﬀective
treatment in the early stages of this disease.
Although the pathogenesis of IPF is not well clariﬁed,
recent studies have focused on dysregulated epithelial-
mesenchymal interactions, an imbalance in T(H)1/T(H)2
cytokine proﬁle, and a potential role for aberrant6 Evidence-Based Complementary and Alternative Medicine
angiogenesis [4]. Proinﬂammatory cytokines like TNF-α,
IL-1β,I L - 6 ,a n dT G F - β might play important roles [28, 29].
In the BALF of bleomycin-treated mice, TNF-α,I L - 1 β,
IL-6, and TGF-β levels of BALF were signiﬁcantly increased.
Although the mechanisms by which PN attenuates lung
ﬁbrosis are unclear, this study shows that TNF-α and IL-6
cytokine levels are signiﬁcantly reduced by PN in alveolar
macrophage culture. In the BALF of mice, TNF-α,I L - 1 β,
IL-6, and TGF-β levels were signiﬁcantly reduced by PN. It
is possible that PN inhibits early phase TNF-α production
by enhancing NO production, to cause cellular damage via
anti-inﬂammatory eﬀects [19, 30]. In a similar manner, PN
can ameliorate the eﬀects of the ﬁbrotic process in the renal
interstitium and block the tubular epithelial-myoﬁbroblast
transdiﬀerentiation [31, 32].
In addition, soluble IL-1β bioactivity and autocrine IL-
1β-dependent IL-6 up-regulation are critical initiators of
ﬁbroblast activation and proliferation that likely play a role
in the ﬁbroproliferative response in human acute lung injury
[33]. In contrast to the BP group (PN started on Day 2),
IL-6 levels and pulmonary ﬁbrosis scores were lower in the
BD group. It is likely that early administration of PN may
stimulate the activation of ﬁbro-proliferation by activating
IL-6.
In the dosage of PN administration, three concentration
levels were administered to animals initially (0.5, 1.0, and
2.0mg/kg/day).ThemortalityrateofC57BL/6micewas57%
for the 7-day course with 2mg/kg/day of PN. In contrast, no
mice died with a dose of 0.5mg/kg/day. To further evaluate
the pathologic changes in dead mice with 2mg/kg/day of
PN, there is a severe inﬂammatory response in the alveolus
and lung parenchyma, with hyaline membrane change.
Features of histopathology are quite similar to those in acute
respiratory distress syndrome (ARDS). As a result, the dose
of 0.5mg/kg/day of PN was used as the experimental dosage
in the animal model.
5. Conclusions
In summary, PN administered in the early ﬁbrotic stage, not
theinﬂammatorystage,cantreatpulmonaryﬁbrosisinduced
by bleomycin.
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